All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

CADLCandel Therapeutics, Inc.
0Calm
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Signing up patientsPhase 245 patientsMain results: Feb 2027
AMGNAmgen
2Calm
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Not started yetPhase 3560 patientsMain results: Dec 30, 2031
IDYAIDEAYA Biosciences
0Calm
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Signing up patientsPhase 3450 patientsMain results: Mar 2034
NVSNovartis Pharmaceuticals
15Calm
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
FinishedPhase 262 patientsMain results: May 17, 2024
COGTCogent Biosciences, Inc.
10Calm
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Signing up patientsPhase 2140 patientsMain results: Sep 19, 2025
NVSNovartis Pharmaceuticals
5Calm
Study of Out of Specification for Tisagenlecleucel
Signing up patientsPhase 3200 patientsMain results: Mar 31, 2027
NTHINeonc Technologies, Inc.
0Calm
NEO100 and High-Grade Meningioma
Signing up patientsPhase 230 patientsMain results: Dec 30, 2026
AZNAstraZeneca
0Calm
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Running, no new patientsPhase 3155 patientsMain results: Jan 3, 2024
AZNAcerta Pharma BV
0Calm
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Running, no new patientsPhase 2107 patientsMain results: Oct 1, 2019
ONCBeOne Medicines
2Calm
A Study of BGB-11417 in Participants With Myeloid Malignancies
Signing up patientsPhase 1/2260 patientsMain results: Aug 31, 2028
BMYBristol-Myers Squibb
10Calm
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Signing up patientsPhase 1/2240 patientsMain results: Apr 23, 2029
PFEPfizer
0Calm
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Running, no new patientsPhase 1/2235 patientsMain results: Feb 26, 2027
BMYBristol-Myers Squibb
10Calm
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Running, no new patientsPhase 2100 patientsMain results: Apr 10, 2025
AZNAstraZeneca
0Calm
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Running, no new patientsPhase 3736 patientsMain results: Feb 27, 2009
AZNAstraZeneca
0Calm
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
Running, no new patientsPhase 3111 patientsMain results: Mar 30, 2026
NTHINeonc Technologies, Inc.
0Calm
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Running, no new patientsPhase 1/249 patientsMain results: Nov 30, 2026
GMABGenmab
0Calm
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Running, no new patientsPhase 3900 patientsMain results: Jun 2027
AZNAstraZeneca
0Calm
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Signing up patientsPhase 2257 patientsMain results: Nov 30, 2028
GILDGilead Sciences
1Calm
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Running, no new patientsPhase 2193 patientsMain results: Mar 2027
GMABGenmab
0Calm
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Running, no new patientsPhase 2184 patientsMain results: Mar 2027
GNPXGenprex, Inc.
0Calm
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Signing up patientsPhase 1/262 patientsMain results: Dec 2027
GILDGilead Sciences
1Calm
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Signing up patientsPhase 1/2250 patientsMain results: Dec 2028
ONCBeOne Medicines
2Calm
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Signing up patientsPhase 1/280 patientsMain results: Dec 2, 2028
AZNAstraZeneca
0Calm
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
Running, no new patientsPhase 2401 patientsMain results: Jan 11, 2021
NVSNovartis Pharmaceuticals
5Calm
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Signing up patientsPhase 3240 patientsMain results: Dec 8, 2028